by Rama Bindu Manchikalapudi

Received: 31 May 2017;  Published: 28 September 2017;  doi: 10.21926/obm.transplant.1703005

Cardiac allograft vasculopathy(CAV) is one of the leading causes of death following the first 5 years after orthotopic heart transplantation(OHT) along with late graft failure( likely secondary to undiagnosed CAV. Currently there is no single medical treatment available for this condition except m [...]

by Mark M Fuster  and Sheri Tran

Received: 16 July 2017;  Published: 12 September 2017;  doi: 10.21926/obm.transplant.1703004

The risk for developing a variety of malignancies is significantly elevated in the setting of lung transplantation. Malignancy remains among the three major causes of death in post-transplant recipients, and the relatively high risk of cancer development as well as metastatic aggression pose special [...]

by In Lam  , Irina Gutman  , Ashley Feist  and Mark Mariski

Received: 10 March 2017;  Published: 22 June 2017;  doi: 10.21926/obm.transplant.1701003

After lung transplant, infection is a leading contributor to morbidity and mortality, and hypogammaglobulinemia (HGG) may be an important risk factor for many of these infections.  Some reports suggest that HGG not only increases the risk of various infections, but also worsens survival.  The incide [...]

by Gerald P. Morris

Received: 22 February 2019;  Published: 11 April 2017;  doi: 10.21926/obm.transplant.1701002

(1) Background: Lung transplantation is an increasingly utilized treatment for end-stage lung disease. Scarcity of organ donors limiting transplantation underscores the importance of optimal histocompatibility testing approaches to facilitate organ allocation and avoid immunologic rejection. Signifi [...]

by Pål Dag Line

Received: 07 April 2017;  Published: 11 April 2017;  doi: 10.21926/obm.transplant.1701001